OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $302,000 Holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 36.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,108 shares of the company’s stock after selling 60,000 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.27% of Leap Therapeutics worth $302,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. HB Wealth Management LLC lifted its stake in shares of Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after buying an additional 26,150 shares during the last quarter. Key Client Fiduciary Advisors LLC lifted its stake in shares of Leap Therapeutics by 12.2% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after buying an additional 39,330 shares during the last quarter. Prosperity Wealth Management Inc. acquired a new stake in shares of Leap Therapeutics during the 4th quarter worth about $63,000. HighTower Advisors LLC lifted its stake in shares of Leap Therapeutics by 105.9% during the 4th quarter. HighTower Advisors LLC now owns 52,500 shares of the company’s stock worth $151,000 after buying an additional 27,000 shares during the last quarter. Finally, Monaco Asset Management SAM acquired a new stake in shares of Leap Therapeutics during the 4th quarter worth about $592,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Stock Performance

NASDAQ:LPTX opened at $0.41 on Thursday. Leap Therapeutics, Inc. has a 52 week low of $0.22 and a 52 week high of $4.79. The firm has a market cap of $16.95 million, a price-to-earnings ratio of -0.21 and a beta of -0.17. The firm’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $1.61.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Tuesday, May 13th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.01. Sell-side analysts anticipate that Leap Therapeutics, Inc. will post -1.84 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on LPTX. Robert W. Baird cut shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th. HC Wainwright reaffirmed a “neutral” rating on shares of Leap Therapeutics in a research report on Thursday, March 27th. Finally, Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.